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Abstract: Ziprasidone is an atypical antipsychotic with a unique receptor-binding proﬁ  le. 
Currently, ziprasidone is approved by the US Food and Drug Administration for the acute treat-
ment of psychosis in schizophrenia and mania in bipolar disorder. When compared to certain 
other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect proﬁ  le, 
especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose 
dysregulation. Taken together, these data suggest that ziprasidone may be a ﬁ  rst line treatment 
for patients with bipolar mania. However, ziprasidone is a relatively new medication for which 
adverse events after long-term use and/or in vulnerable patient populations must be studied. 
Unstudied areas of particular importance include the efﬁ  cacy and safety of ziprasidone in the 
treatment of bipolar depression and relapse prevention of mania as, well as in the subpopula-
tions of pregnant women, the elderly and pediatric patients. The emergence of mania in patients 
taking ziprasidone is another topic for further study.
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Introduction
There is a growing body of evidence for the use of atypical antipsychotics in the 
treatment of bipolar disorder both for acute mania and long-term therapy (Chengappa 
et al 2004; Vieta 2005; Vornik and Hirschfeld 2005). Concerns that arise with the use 
of antipsychotics in bipolar patients revolve around whether clinicians are exposing 
patients to unnecessary risks, especially for those patients without psychosis for 
whom other effective treatments are available. With the use of any antipsychotic 
medication, the development of extrapyramidal movement side effects, particularly 
tardive dyskinisia, is a concern. Patients receiving typical antipsychotics carry a risk 
of developing tardive dyskinisia of approximately 4%–5% per year (APA 1992). 
The rate of akathisia among young patients treated with conventional antipsychotic 
drugs is up to 90% and decreases as the age of the patients increases (Wirshing 2001). 
Even among 65 year olds, the rate of akathisia with typical antipsychotic medication 
treatment is 15% (Wirshing 2001). Evidence suggests that patients with mood disor-
ders are more susceptible to the extrapyramidal side effects (EPS) of antipsychotics 
than patients with schizophrenia (Kane and Smith 1982; Mukherjee et al 1986; 
Nasrallah et al 1988). While the risk of developing EPS appears lower with atypical 
antipsychotics, little long-term treatment data have been collected to clarify the extent 
of the risk (Pierre 2005). The recently published Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE) study revealed that the rates of EPS in patients 
with schizophrenia were not signiﬁ  cantly different between patients treated with the 
typical antipsychotic perphenazine and the various atypical antipsychotic drugs, though 
patients with a history of tardive dyskinisia were not randomized to the perphenazine 
arm of the study (Lieberman et al 2005).Neuropsychiatric Disease and Treatment 2007:3(6) 824
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Potential metabolic side effects must also be weighed 
when considering the use of antipsychotic medications. 
Weight gain, increase in plasma lipid concentrations and 
the development of type II diabetes have been associated 
with certain atypical antipsychotic medications (Ananth et al 
2004a; Newcomer 2005). The risk of development of the 
full metabolic syndrome appears to be different among the 
members of the atypical antipsychotic drug class (Newcomer 
2005). Clozapine and olanzapine have been associated with 
the highest rates of weight gain, obesity, glucose dysregula-
tion, diabetes and hyperlipidemia as well as life threatening 
diabetic ketoacidosis (Newcomer 2005). Risperidone and 
quetiapine have been suggested to exhibit a moderate risk 
for these metabolic abnormalities, whereas ziprasidone and 
aripiprazole have been shown not only to have little or no 
effect on body weight, lipids or glucose (Newcomer 2005) 
but often improve these indices when patients are switched 
from olanzapine and risperidone (Weiden et al 2003).
Ziprasidone is an atypical antipsychotic of the benziso-
thiazolylpiperazine family approved by the FDA for use in 
the acute treatment of schizophrenia and schizoaffective 
disorder in February 2001. The available data, both basic 
pharmacology and clinical efﬁ  cacy and tolerability have 
been comprehensively reviewed (Nemeroff et al 2005). 
Ziprasidone subsequently was approved by the FDA for the 
treatment of acute bipolar mania including mixed episodes 
in August 2004 (Nemeroff et al 2005). There is also some 
evidence that ziprasidone may be efﬁ  cacious converting 
antidepressant non-responders to responders in patients with 
unipolar depression (Papakostas et al 2004), in the treat-
ment of agitation in patients with dementia (Cole et al 2005; 
Greco et al 2005; Berkowitz 2003), and in the treatment of 
delirium (Young and Lujan 2004; Leso and Schwartz 2002). 
The pharmacologic proﬁ  le of ziprasidone includes the fol-
lowing: antagonist activity at dopamine (DA) D2, serotonin 
5-HT1D and 5-HT2C receptors, inverse agonist activity at 
serotonin 5-HT2A receptors and agonist activity at 5-HT1A 
receptors (Nemeroff et al 2005). Ziprasidone is the most 
potent antagonist of 5-HT2A receptors of the available atypical 
antipsychotic drugs (Schmidt et al 2001). It is also a relatively 
potent inhibitor of serotonin (5-HT) and norepinephrine (NE) 
reuptake in vitro, unique among the atypical antipsychotics 
(Schmidt et al 2001). Whether this effect occurs in vivo in 
light of ziprasidone’s tight protein binding in serum remains 
unknown, but it is of considerable interest because these 
properties are shared with clinically effective antidepres-
sants. This review focuses on the efﬁ  cacy and tolerability 
of ziprasidone in patients with bipolar disorder.
Pharmacokinetics 
and pharmacodynamics
Ziprasidone oral bioavailability is about 60% in healthy 
volunteers when taken with food, which increases absorp-
tion by more than 50%. Peak plasma concentrations occur 
in 3.7–4.7 hours (Miceli et al 2000). The elimination half-
life of oral ziprasidone given at doses of 80–120 mg/day 
is approximately 10 hours, thus it is recommended that 
ziprasidone be taken twice daily (Patel and Keck 2006). 
This dosing schedule may increase the possibility of missed 
doses and breakthrough symptoms, though this has not been 
studied. Because ziprasidone half-life is longer at higher 
doses (Miceli et al 2000), it has been proposed that once a day 
dosing may be appropriate at doses greater than 120 mg/day 
(Patel and Keck 2006). The safety and efﬁ  cacy of once daily 
dosing of ziprasidone has not been studied.
Efﬁ  cacy
Monotherapy
Acute mania
Two 3-week double-blind, placebo-controlled trials have 
been conducted to determine the efﬁ  cacy and tolerability 
of ziprasidone in patients with acute mania (see Table 1 
and Table 2). Keck et al (2003) reported the results of a 
multicenter (21 US and 3 Brazilian) trial of 210 patients with 
acute mania with a primary diagnosis of Bipolar I disorder, 
Table 1 Safety and Tolerability Trial I (Keck et al 2003)
  Placebo Group  Ziprasidone Group
Number of patients  66  131
Mean Age (range)  37 (19–64)  39 (18–66)
Bipolar Episode   63%/37%  65%/35%
Manic/Mixed
Baseline MRS  26.7  27.0
Mean reduction MRS  7.8  12.4 (p   0.005)
Responders 35%  50%  (p    0.05)
Reduction in CGI severity   0.9  1.3 (p   0.01)
Reduction in PANSS  2.0  4.8 (p   0.001)
Discontinuation Rates  55.7%  46.4% *
Withdrawal secondary to   4.3%  6.4% *
adverse events   
Adverse Events, total  77.1%  90.0% *
Somnolence 12.9%  37.1%  *
Headache 18.6%  21.4%  *
Dizziness 10.0%  22.1%  *
Hypertonia 2.9%  11.4%  *
Nausea 10.0%  11.4%  *
Akathisia 5.7%  10.7%  *
Mean QTc  Not reported  11 msec
*p value not provided.
Average ziprasidone dose during days 15–21: 130.1mg/day.Neuropsychiatric Disease and Treatment 2007:3(6) 825
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most recent episode manic or mixed as conﬁ  rmed by the 
Structural Clinical Interview for DSM-IV Axis I Disorders, 
Patient Edition (SCID-P). Patients were required to have a 
Mania Rating Scale (MRS) (Endicott and Spitzer 1978) score 
of  14 within 12 hours of the ﬁ  rst dose of the double-blind 
medication. All psychotropic medications except lorazepam, 
temazepam and medications to manage movement disorders 
were discontinued. Patients received placebo single-blind 
during a washout period of 1–7 days before being randomly 
assigned to ziprasidone treatment or placebo groups in a 
2:1 ratio. Ziprasidone was initiated at 40 mg bid on the ﬁ  rst 
day, and then increased to 80 mg bid. Doses were adjusted 
to in the range of 80–160 mg per day during the remainder 
of the trial based on tolerability and efﬁ  cacy. Raters blinded 
to the patients’ medications evaluated the patients using the 
Schedule for Affective Disorders and Schizophrenia, Change 
Version (SADS-C)(Endicott and Spitzer 1978), which 
contains the MRS, Positive and Negative Syndrome Scale 
(PANSS) (Kay et al 1987), investigator-rated Clinical Global 
Impression (CGI) severity scale (Guy 1976), investigator-
rated CGI improvement scale, and Global Assessment 
of Functioning Scale (GAF) (Guy 1976). A difference of 
5 points on the MRS was deﬁ  ned a priori as the minimal 
clinically relevant difference in endpoint values. Primary efﬁ  -
cacy analyses were the differences on MRS and CGI severity 
scale scores from baseline to endpoint in the ziprasidone group 
compared to the placebo group on an intent-to-treat basis. The 
mean dose of ziprasidone during days 8 to 14 of the trial was 
139.1 mg/day and during days 15–21, it was 130.1 mg/day.
By day 7, the ziprasidone-treated patients showed signiﬁ  cant 
improvement on all of the symptom severity scales. The 
ziprasidone-treated patients showed a mean reduction of 
12.4 points in their MRS scores, the placebo-treated patients, 
a decrease of only 7.8 points. This difference, while sta-
tistically signiﬁ  cant, did not meet the minimally clinically 
relevant superiority standard established a priori. By day 2 
the mean change on the MRS between the two groups was 
statistically signiﬁ  cant (p   0.003) and this difference was 
maintained until the end of the 3-week trial (p   0.001). 
One-half of the ziprasidone-treated patients were responders 
(as deﬁ  ned by a  50 % improvement of MRS) versus only 
35% of the placebo-treated group (p   0.05). Statistically 
signiﬁ  cant differences on CGI severity and improvement 
scales were observed by day 4 in the ziprasidone group. At 
endpoint, the mean CGI severity scores as compared to base-
line were reduced by 1.3 in the ziprasidone-treated patients 
and 0.9 in the placebo-treated patients (p   0.01). PANSS 
scores at endpoint were signiﬁ  cantly reduced from baseline 
in the ziprasidone group compared to the placebo group (4.8 
versus 2.0, p   0.001). GAF scores were higher at endpoint 
in both groups, though greater in the ziprasidone-treated 
patients (15.3 versus 8.3, p   0.005). Discontinuation rates 
were lower in the ziprasidone-treated group (46.4%) when 
compared to the placebo group (55.7%).
Patient withdrawal secondary to adverse events was 
6.4% in the ziprasidone-treated group and 4.3% in the 
placebo group. Adverse events occurred in 90.0% of the 
patients receiving ziprasidone and 77.1% of those receiv-
ing placebo. The vast majority, 96% and 99%, of these 
adverse events were rated as mild or moderate in severity 
in the ziprasidone and placebo groups, respectively. No 
serious adverse events occurred in either group. Events that 
occurred more often in the ziprasidone-treated group were 
somnolence (37.1% versus 12.9%), headache (21.4% versus 
18.6%), dizziness (22.1% versus 10.0%), hypertonia (11.4% 
versus 2.9%), nausea (11.4% versus 10.0%) and akathisia 
(10.7% versus 5.7%). No changes in blood pressure, pulse 
rate or body weight were observed in either treatment group. 
Signiﬁ  cant changes in laboratory values were found in less 
that 2% of patients in both groups. Pre- and post-treatment 
Table 2 Safety and Tolerability Trial II (Potkin et al 2005)
  Placebo Group  Ziprasidone Group
Number of patients  66  139
Mean Age (range)  39 (10–71)  39 (19–70)
Bipolar Episode Manic/Mixed  61%/39%  59%/41%
Baseline MRS  26.4  26.2
Reduction in MRS  5.6  11.1 (p   0.01)
Reduction in CGI severity   0.43  1.09 (p   0.001)
Reduction in PANSS  3.55  12.01 (p   0.01)
Discontinuation Rates  46%  39% *
Treatment-related   1.5%  5.8% (p = 0.20)
discontinuation  
Adverse Events, total  67%  78% *
Somnolence 6.1%  22.3%  (p  = 0.002)
Headache 7.6%  12.2%  (p  = 0.122)
Extrapyramidal Syndrome  1.5%  10.8% (p = 0.013)
Dizziness 1.5%  10.1%  (p  = 0.018)
Akathisia 4.5%  9.4%  (p  = 0.167)
Nausea 1.5%  6.5%  (p  = 0.094)
Asthenia 1.5%  5.0%  TK
Abdominal Pain  7.6%  1.4% TK
Mean Lengthening of QTc  2.1msec  10.1 msec 
Median Weight Change  0 kg  0 kg
Weight Gain  7%   3.4%  4.8% *
Mean change in total   −1mg/dL 1mg/dL
cholesterol  
Mean change in total   −8 mg/dL  −1mg/dL
triglycerides  
*p value not provided.
Average ziprasidone dose during days 15–21: 126.5 mg/day.
Overall mean ziprasidone dose: 112 mg/day.Neuropsychiatric Disease and Treatment 2007:3(6) 826
Nicolson and Nemeroff
ECG data revealed a mean QTc interval prolongation of 
11 msec in the ziprasidone-treated group. No patient had a 
QTc interval of greater than 500 msec.
A second and similar multisite treatment trial of adult 
inpatients with a primary diagnosis of Bipolar I disorder, 
most recent episode manic or mixed was reported by Potkin 
et al (2005). This study utilized inclusion criteria and dos-
ing schedules similar to those used in the Keck et al (2003) 
study. The patients were evaluated using the Schedule for 
Affective Disorders and Schizophrenia, Change Bipolar Scale 
(SADS-CB) (Endicott and Spitzer 1978) which included 
the extracted Hamilton Depression Rating Scale (HAM-D) 
(Endicott et al 1981) and Montgomery Asberg Depression Rat-
ing Scale (MADRS) (Montgomery and Asberg 1979) scores. 
The primary efﬁ  cacy endpoint was mean MRS change from 
baseline to endpoint. A total of 206 patients were randomized. 
The mean ziprasidone dose was 126 mg/day. A statistically 
signiﬁ  cant difference (p   0.05) in mean MRS scores was 
noted on the second day of the study, as well as on day 21 
(p   0.01). The percentage of patients classiﬁ  ed as responders 
( 50% improvement in symptom severity) was 46% in the 
ziprasidone group and 29% in the placebo group (p   0.05). 
Mean CGI severity scale scores of the ziprasidone group 
showed signiﬁ  cant improvement versus the placebo group at 
day 2 (p   0.05) and this difference was maintained until day 
21 (p   0.001). Patients in the ziprasidone group experienced 
greater improvements from baseline to endpoint in PANSS 
Total and Positive Subscales scores compared to those in the 
placebo group (p   0.01). The magnitude of the GAF score 
improvement in the ziprasidone group was more than twice that 
observed in the placebo group (15.82 versus 7.59, p   0.001). 
Discontinuation rates were lower in the ziprasidone-treated 
patients (39%) than in the placebo group (46%). In the zipra-
sidone group, 6.5% dropped out because of adverse events that 
were considered treatment-related. Treatment-related dropouts 
comprised 1.5% of the placebo group. Treatment-emergent 
side effects were reported in 78% of ziprasidone-treated 
and in 67% of placebo-treated patients. Events that occurred
more often in the ziprasidone-treated group were somnolence 
(22.3% versus 6.1%), headache (12.2% versus 7.6%), extrapy-
ramidal syndrome (10.8% versus 1.5%), dizziness (10.1% ver-
sus 1.5%), akathisia (9.4% versus 4.5%), tremor (7.9% versus 
1.5%), nausea (6.5% versus 1.5%), and asthenia (5.0% versus 
1.5%). Mean changes in blood pressure, pulse rate or body 
weight were not considered clinically signiﬁ  cant in either 
group. Signiﬁ  cant changes in laboratory values were found in 
less that 2% of patients in both groups. 21% of patients taking 
ziprasidone (versus 19% in the placebo group) developed
elevations in triglycerides. However, the mean triglyceride 
level in the treatment group dropped by 1mg/dL over the course 
of the trial. Electrocardiogram (ECG) evaluations revealed a
mean QTc interval prolongation of 10.1 msec in the 
ziprasidone-treated group versus 2.1 msec in the placebo 
group. No patient had a QTc interval of greater than 480 msec. 
Serious adverse events were reported in 4 patients in the 
ziprasidone group and 1 in the placebo group, though none of 
these events was considered to be related to the study medica-
tion. Taken together, these results indicate that ziprasidone is 
effective and safe in treating acute mania.
Mixed mania
A pooled analysis of the 2 randomized, double-blind, 
placebo-controlled 21-day trials of ziprasidone in patients 
with acute bipolar mania described in detail above examined 
the response of patient subgroups, including those with 
mixed mania who were treated with ziprasidone (n = 101) 
or placebo (n = 50) (Potkin et al 2004) (see Figure 1). The 
mean decrease in MRS scores for patients with mixed 
mania in the ziprasidone group was signiﬁ  cantly greater 
than those in the placebo group (p   0.01 at 14 days and 
p   0.05 at 21 days).
Psychotic mania
In the pooled analysis discussed above, patients with psy-
chotic symptoms who were in the ziprasidone treatment 
group (n = 116) had nearly double the magnitude of decrease 
in their MRS scores by endpoint when compared to psychotic 
patients who received placebo (n = 52) (see Figure 2). This 
difference was statistically signiﬁ  cant at day 4 (p   0.01) 
and was maintained to endpoint (Potkin et al 2004).
Depression as part of mixed or pure mania
Among patients with depressive symptoms in the Potkin et al 
(2005) bipolar mania trial, treatment with ziprasidone was 
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Figure 1 Mean decrease in MRS pure mania vs mixed episodes after 21 days 
(estimated from Potkin et al 2004).Neuropsychiatric Disease and Treatment 2007:3(6) 827
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associated with a mean decrease of 2.43 points on the 
HAM-D compared to 1.37 points in the placebo-treated 
patients (Potkin et al 2004; Potkin et al 2005). Mean MADRS 
score reduction in patients who had baseline MADRS scores 
of   14 at baseline was 8.6 in the ziprasidone-treated patients 
(n = 52) and 4.5 (n = 26) in the placebo-treated group. Neither 
the difference in HAM-D or MADRS scores at endpoint, 
however, attained statistical signiﬁ  cance. Another pooled 
analysis revealed that in patients with mixed mania and a 
baseline HAM-D score  14, ziprasidone produced greater 
improvement (p   0.05) than placebo in HAM-D scores 
from day 2–21 (Keck et al 2004).
Combination/augmentation studies
Although monotherapy with a traditional mood stabilizer has 
been the recommended initial treatment for bipolar disorder 
(APA 2002), there is a growing body of evidence that sug-
gests that combination therapy with a mood stabilizer and an 
antipsychotic medication is more efﬁ  cacious, especially in 
cases of severe mania (Bowden 2005). The Texas Medica-
tion Algorithm Project (TMAP) also developed guidelines 
for treatment of Bipolar Disorder (Suppes and Dennehy 
2001). The initial TMAP algorithm for mania/hypomania 
recommended the atypical antipsychotic, olanzapine, as an 
initial monotherapy option (Stage 1) along with lithium and 
divalproex as other options. Patients with psychotic mania 
who failed to fully respond to initial treatment were suggested 
to be then put on a combination of lithium or anticonvulsant 
plus an atypical antipsychotic, which could be olanzapine, 
risperidone, quetiapine or ziprasidone. In 2005, the algorithm 
was revised to include aripiprazole, risperidone, quetiapine, 
and ziprasidone as Stage 1a options along with lithium and 
divalproex (Suppes et al 2005). Olanzapine, however, was 
categorized, along with carbamazepine, as a Stage 1b choice 
due to “safety and other concerns”.
Weisler et al reported that the addition of ziprasidone to 
lithium treatment reduced time to improvement (Weisler et al 
2003) (see Table 3). This 21-day, double-blind trial random-
ized 205 patients with Bipolar I disorder who were taking 
lithium and had MRS   14 to ziprasidone or placebo. Dosage 
of lithium was adjusted to maintain a plasma lithium level of 
0.8–1.2 mEq/L. Ziprasidone was initiated at a dose of 80 mg 
on day 1 and 160 mg on day 2, with dose adjustments in 
the range of 80–160 mg per day during days 3–21. Primary 
efﬁ  cacy variables were improvement in MRS and CGI-
severity scores. By day 4, signiﬁ  cantly greater improvement 
was observed in the ziprasidone plus lithium treated patients 
compared to the placebo plus lithium treated patients in MRS 
(2.31 versus 1.59, p   0.05) and CGI-severity (2.0 versus 
0.12, p   0.01). The signiﬁ  cant differences in the improve-
ments on these measures between the treatment groups disap-
peared by day 14, though numerically greater improvement 
was maintained through the end of the study. The PANSS 
scores of the ziprasidone/lithium group were signiﬁ  cantly 
better than those of the lithium only group on day 21 (13.4 
versus 8.45, p   0.01). This led the authors to conclude that 
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Figure 2 Decrease in MRS psychotic mania vs non-psychotic mania after 21 days 
(estimated from Potkin et al 2004).
Table 3 Ziprasidone augmentation with lithium (Weisler
et al 2003)
  Lithium +   Lithium +
 Placebo  Ziprasidone
 Group  Group
Number of Patients  103  102
Mean Age in yrs (range)  37 (18–70)  37 (19–71)
Type of Manic Episode:   68%/32%  61%/39%
Pure/Mixed  
Discontinued 28.2%  30.7%  *
Mean reduction MRS  1.59  2.31 (p   0.05)
(at 4 days)   
Mean reduction MRS   5.51  6.5 (not statistically 
(at 14 days)    signiﬁ  cant)
Reduction in CGI severity   0.12  2.0 (p   0.01)
(at 4 days)   
Reduction in PANSS  8.45  13.4 (p   0.01)
(at 21 days)   
Withdrawal secondary  4%  8% *
to adverse events   
Adverse Events, total  76%  86% *
Somnolence 12%  34%  *
Extrapyramidal Syndrome  4%  22% *
Dizziness 6%  13%  *
Agitation 2%  11%  *
Abnormal Vision  4%  10% *
Vomitting 5%  10%  *
Akathisia 0%  9%  *
Dystonia 0%  9%  *
Mean Lengthening of QTc  6.1 msec  11.8 msec
*p value not provided.
Average ziprasidone dose: 131.1 mg/day.Neuropsychiatric Disease and Treatment 2007:3(6) 828
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augmentation with ziprasidone helped provide rapid reduc-
tion of manic symptoms and greater improvement in overall 
psychopathology, although symptoms of mania were not 
signiﬁ  cantly decreased by ziprasidone augmentation.
A 52-week open-label extension revealed that 89 
patients treated with ziprasidone and concomitant mood 
stabilizers and/or antidepressants had a mean MRS score at 
all study visits that was signiﬁ  cantly (p   0.01) improved 
from baseline (Weisler et al 2004) (see Table 4). The 
incidence of treatment-emergent side effects included: som-
nolence (55.1%), abnormal vision (23.6%), tremor (22.5), 
extrapyramidal syndrome (21.3%), dizziness (20.2%), head-
ache (19.1%), nausea (19.1%), anxiety (16.9%), insomnia 
(16.9%), and akathisia (12.4%). Simpson-Angus and Barnes 
Akathisia scores changed minimally. No QTc intervals 
over 480 msec were recorded despite coadministration 
of ziprasidone with lithium. No increases in body weight 
or serum cholesterol levels were observed. A signiﬁ  cant 
decrease in serum triglyceride levels was noted in the 
ziprasidone group (p = 0.01).
Plasma lithium levels are not altered by the addition of 
oral ziprasidone in healthy patients (Apseloff et al 2000). 
However adverse events have been reported during 
ziprasidone augmentation of lithium therapy. One report 
documented two schizoaffective patients who experienced 
abrupt rises in plasma lithium levels and symptoms of lithium 
toxicity within two days of the initiation of intramuscular 
ziprasidone treatment (Miodownik et al 2005).
Comparison of ziprasidone with other 
atypical antipsychotics in acute mania
A recent meta-analysis concluded that each of the 5 newer 
agents (aripiprazole, olanzapine, quetiapine, risperidone and 
ziprasidone) are superior to placebo in the treatment of bipo-
lar mania and that efﬁ  cacy differences between the atypical 
antipsychotics, if they exist, are small (Perlis 2006). Primary 
outcome measures were changes in the MRS or Young Mania 
Rating Scale (YMRS) (Young et al 1978) scores between 
baseline and endpoint (either day 21 or 28). Data from 12 
placebo-controlled trials were evaluated, including 1881 
drug-treated and 1233 placebo-treated patients. Included 
were at least two trials for each of the 5 atypical antipsychotic 
medications. No statistically signiﬁ  cant differences were 
found among the medications. Two studies of each of 4 drugs 
(aripiprazole, olanzapine, risperidone and ziprasidone) used 
50% reduction in MRS or YMRS as the criteria for response. 
The overall response rates for the atypicals was 53% as com-
pared to 30% for placebo. Ziprasidone had the highest odds 
ratio for response relative to placebo among the medications 
studied, though the difference was not statistically signiﬁ  cant. 
Six add-on therapy studies were also included in the meta-
analysis. Although ziprasidone showed the smallest difference 
between the antipsychotic/mood stabilizer treatment versus 
mood stabilizer monotherapy, the difference between zipra-
sidone and other atypical medications was not statistically 
signiﬁ  cant. Because of the minimal differences in treatment 
effects among published trials of atypical antipsychotic 
medications for acute mania, the authors recommended that 
treatment selection be based on factors such as maintenance 
efﬁ  cacy, tolerability, safety and cost.
Maintenance studies
A 52-week, open-label extension of a 21-day placebo-
controlled trial of ziprasidone in patients with acute mania 
revealed sustained improvement in manic and depressive 
symptoms (Keck et al 2004) (see Table 5). Of the 107 
patients who entered the extension, 39 remained in the 
study for the entire year. Only 8.7% of patients discontinued 
due to treatment related adverse events. The mean dura-
tion of treatment was 105 days, with the mean ziprasidone 
Table 4 Adjunctive ziprasidone with lithium 52-week open label 
extension (Weisler et al 2004)
Number of patients at   89 (41 from ziprasidone + 
extension study baseline  lithium, 48 from placebo + 
 lithium)
Mean age in years (range)  37 (18–71)
Episode at Acute Study   46%/54%
baseline Pure Mania/Mixed 
Reduction in MRS at 52   20.70 (p   0.01)
weeks for those from  
ziprasidone arm of acute  
study (n = 10) 
Gained  7% of baseline   12.1 % 
body weight 
Lost  7% of baseline body   10.6%
weight 
Mean change in weight  −0.76 lbs *
Mean change in serum   −43.27 (p = 0.01)
triglycerides 
Discontinuation rate  56% 
Discontinuation rate due to   12.4% 
adverse events 
Adverse Events  90.0% 
Somnolence 55.1% 
Abnormal Vision  23.6%
Tremor 22.5%
EPS 21.3%
Dizziness 20.2%
*p value not provided.
Mean ziprasidone dose at 52 weeks (n = 10): 92.6 mg/day.Neuropsychiatric Disease and Treatment 2007:3(6) 829
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dose 132 mg per day. Mean MRS and CGI-severity scores 
maintained statistically signiﬁ  cant improvement over base-
line scores throughout the one-year follow-up (p   0.0001). 
There was a reduction in mean body weight over the 
52-week period with an equal number (11%) of patients 
experiencing signiﬁ  cant ( 7% of baseline weight) weight 
loss and gain. Patients experienced a small (1.59 mg/dL) 
rise in mean plasma cholesterol levels and a moderate 
(14.8 mg/dL) decrease in mean plasma triglyceride levels. 
There was little change from baseline to endpoint in scales 
measuring extrapyramidal symptoms.
IM ziprasidone studies
In 2002, ziprasidone became the ﬁ  rst atypical antipsychotic 
available in intramuscular (IM) form for the treatment of 
acute agitation in psychotic patients. In a randomized double-
blind 24 hour study which included patients with bipolar 
disorder or schizoaffective disorder, bipolar type, improve-
ments in the PANSS Agitation subscale, Behavioral Activity 
Rating Scale (BARS) and CGI-severity scores were noted 
within 15 minutes of receiving the 20 mg dose (Daniel et al 
2001). In a subgroup analysis of 2 randomized, double-blind, 
ﬁ  xed-dose, 24-hour studies of the efﬁ  cacy of IM ziprasidone, 
patients with bipolar disorder or schizoaffective disorder, 
bipolar type showed improvements in the PANSS Agitation 
subscale, Behavioral Activity Rating Scale (BARS) and CGI-
severity scores within 15 minutes of receiving the 20 mg dose 
(Daniel et al 2004). The 10 mg dose was not as effective. 
There was an 80% responder rate (deﬁ  ned by a  2 point 
decrease in BARS 90 minutes after the ﬁ  rst dose) with the 
20 mg dose, a 58% responder rate with the 10 mg dose, and an 
18.2% responder rate with the 2 mg control dose (p   0.01). 
Adverse events were not different in patients receiving the 
2 mg control dose compared to patients receiving the 10 mg 
and 20 mg dose. No dystonia or excessive sedation was 
reported in the 10 mg (n = 20) and 20 mg (n = 15) groups. 
One patient in the 10 mg group experienced akathisia. A natu-
ralistic study conducted on a psychiatric emergency service 
(Preval 2005) reported a decrease in the Behavioral Activity 
Rating Scale (BARS) (Swift 2002) agitation scores using 
20 mg IM ziprasidone in 110 patients with various diagnoses. 
Scores decreased signiﬁ  cantly from baseline after 15 minutes 
(p   0.5) and were maintained at 2 hours (p   0.01). None 
of the patients given ziprasidone showed lasting side effects, 
though one patient had an acute dystonic reaction, which 
responded rapidly to diphenhydramine. ECGs obtained in 
19 patients revealed no QTc longer than 460 msec.
Pediatric bipolar disorder
While there are no FDA-approved treatments for mania in 
children and adolescents, atypical antipsychotics have been 
used increasingly in this population (Kowatch and DelBello 
2006). Barnett (2004) reported on 4 patients (ages 7–16) 
who successfully were switched from other medications to 
ziprasidone to control hypomanic and depressive symptoms 
and in two cases, auditory hallucinations, in the absence of 
other psychotic symptoms. After switching to ziprasidone 
these patients experienced relief of symptoms and reported 
a euthymic and stable mood. Each of the patients were 
maintained on daily doses of ziprasidone ranging from 
40–80 mg per day. One patient experienced akathisia at 
a dose of 20 mg tid, which completely abated after a dose 
reduction to 20 mg bid.
Safety and tolerability
Extrapyramidal symptoms
A ﬂ  exible-dose trial in patients with schizophrenia compared 
the development of extrapyramidal side effects in patients 
taking ziprasidone (mean 116 mg/day) and haloperidol 
(mean 8.6 mg/day) (Hirsch et al 2002). Akathisia (14% 
versus 16%), hypertonia (2% versus 7%), tremor (6% versus 
10%), and extrapyramidal syndrome (1% versus 5%) were 
all less common with ziprasidone than with haloperidol. 
Recent case reports have implicated ziprasidone in acute 
dystonic reactions in adults with schizophrenia and bipolar 
disorder (Mason et al 2005; Weinstein et al 2006), as well 
as in a child with developmental delay and attention-deﬁ  cit/
hyperactivity disorder (Ramos et al 2003). There have also 
been several reports of tardive dyskinesia reemergence dur-
ing ziprasidone treatment (Rosenquist et al 2002; Ananth, 
Table 5 Ziprasidone 52-week open label extension (Keck 
et al 2004)
Number of Patients  127
Mean Age in yrs (range)  39 (18–66)
Type of Manic Episode:   69%/31%
Pure/Mixed 
Discontinued 62.2%
Withdrawal secondary to   8.7%
adverse events 
Mean Change in plasma   1.59 mg/dl
cholesterol 
Mean Change in plasma   −14.8 mg/dl
triglycerides 
Mean Weight Change  −2.52 kg
Weight Gain ≥ 7%   11.0%
Weight Gain ≤ 7%  11.0%
Mean ziprasidone dose: 122.4 mg/day.Neuropsychiatric Disease and Treatment 2007:3(6) 830
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Burgoyne et al 2004; Mendhekar 2005) and its emergence 
during ziprasidone treatment (Ananth, Burgoyne et al 2004; 
Keck et al 2004). A recent study suggests that the frequency 
of movement side effects of atypical antipsychotics may be 
much higher (over 50%) than those reported in clinical trials 
(Ghaemi et al 2006). Also of importance is that more than 
half of the patients enrolled in the ziprasidone trials were 
receiving benzodiazepines, anticholinergic or beta-blocking 
agents (Gentile 2007). Thus the EPS rates during ziprasidone 
treatment may be underestimated.
The rates of akathisia in the ziprasidone studies in acute 
mania have been reported at 10.7% and 9.4% (Keck et al 
2003; Potkin et al 2005). In the augmentation trial with 
lithium, 9% of the ziprasidone-treated group reported akathi-
sia, versus 0% in the lithium-only group (Weisler et al 2003). 
Akathisia rates with conventional antipsychotics have been 
estimated from 20% to 75% (APA 2000). Other atypical 
antipsychotics have also been associated with akathisia dur-
ing monotherapy trials of bipolar patients, including aripip-
razole (6.5%–11.4%), olanzapine (0%–9.6%) and quetiapine 
(3.6%–5.9%) (Gentile 2007). In short term bipolar mania 
trials, aripiprazole treatment was associated with akathisia 
in 15% of treated patients (Bristol-Myers Squibb Company 
2006). The rate of akathisia with risperidone in short-term 
bipolar mania trials was 16% (Janssen 2007). Antidepres-
sant medications have been associated with akathisia (Gill 
et al 1997). The incidence of ﬂ  uoxetine-induced akathisia 
is estimated between 9.8% and 25% (Lipinski et al 1989). 
The pathophysiology of akathisia is thought to be primarily 
due to a decrease in dopamine activity in the ventral teg-
mental area, a potential consequence of both the dopamine 
blockade by antipsychotics and of the enhanced serotinergic 
and noradrenergic neurotransmission by antidepressants 
(Catalano et al 2005). The antipsychotic and antidepressant 
effects of ziprasidone may both contribute to the development 
of akathisia in patients taking ziprasidone.
Neuroleptic malignant syndrome
Because patients treated with antipsychotic drugs are at risk 
for the development of neuroleptic malignant syndrome 
(NMS) (Keck et al 1989; Caroff and Mann 1993), physicians 
treating bipolar patients with atypical antipsychotic medica-
tions must be aware of this possibility. A review of NMS cases 
associated with the use of atypical antipsychotics revealed 68 
cases in the literature, though no ziprasidone-induced NMS 
cases were identiﬁ  ed (Anath et al 2004b). Since then, there 
have been a few cases of NMS associated with ziprasidone 
treatment (Murty et al 2002; Yang and McNeely 2002; 
Liebold et al 2004; Gray 2004; Ozen et al 2007), as well as 
one case of NMS associated with the combination of lithium 
and ziprasidone (Borovicka et al 2006).
Weight gain
While evidence mounts that atypical antipsychotics as a 
class may have deleterious effects on patients’ weight, 
ziprasidone may have an advantage by promoting less 
weight gain (McIntyre and Konarski 2005; Marken and Pies 
2006). However the data on weight changes with ziprasi-
done are not conclusive. In short term studies of ziprasidone 
treatment have shown the risk of weight gain  7% of body 
weight to be as high as 10% (Sprague 2004). In a meta-
analysis calculating the effects of antipsychotic medication 
on weight, 10 weeks of ziprasidone treatment was associ-
ated with a mean increase in weight of 0.04 kg (Allison et al 
1999). Placebo was associated with a reduction in weight 
of 0.39 kg. Other atypical antipsychotic were associated 
with weight gain after 10 weeks of treatment, including 
clozapine (4.45 kg), olanzapine (4.15 kg), and risperidone 
(2.10 kg). Studies in patients with schizophrenia treated 
with ziprasidone for at least 1 year have shown no effect 
on weight, though conclusions are limited by the small 
sample size (less than 400 total patients) (Gentile 2006). 
In patients with bipolar disorder, the data on weight change 
are less substantial.
Cardiac adverse effects
Since the initial clinical trials, ziprasidone has been known 
to prolong the QTc interval of some patients. As discussed 
above, in the two pivotal clinical trials demonstrating the 
efﬁ  cacy of ziprasidone in the treatment of mania, mean QTc 
lengthening was reported at 11 msec (Keck et al 2003) and 
10.1 msec (Potkin et al 2005). A report studying the effects 
of six antipsychotics (thioridazine, haloperidol, risperidone, 
olanzapine, quetiapine and ziprasidone) on QTc interval 
showed that none of the atypical antipsychotics studied 
increased the QTc by more than 16 msec and that their use 
does not appear to be associated with an increased risk of 
cardiac events (Harrigan 2004). The mean QTc interval 
lengthening was 15.9 msec for subjects taking ziprasidone. 
There is one case report of a patient who experienced QTc 
prolongation during treatment with ziprasidone associ-
ated with an asymptomatic episode of torsades de pointes 
(Heinrich 2006). During the treatment of this patient, on 
two occasions, discontinuation of ziprasidone was associ-
ated with a shortening of the QTc. As the authors note, the 
patient had multiple problems and was treated with other Neuropsychiatric Disease and Treatment 2007:3(6) 831
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medications, including lithium, which has been associated 
with arrhythmias and QT alterations. A case series examined 
the effect of ziprasidone on the ECGs of 15 patients receiving 
above the recommended daily dose of ziprasidone (Levy et al 
2004). The mean baseline QTc of these patients (including 
two patients already taking 160 mg/day of ziprasidone) was 
415 msec. After the patients had received at least one week 
of their maximum ziprasidone dose (240–320 mg/day), the 
mean QTc had increased to 416 msec. The maximum post 
treatment QTc interval was 452 msec. The authors concluded 
that if the study could be replicated in a double-blind placebo 
controlled trial, high dose ziprasidone potentially could safely 
be used in certain populations. Nonetheless, ziprasidone is 
contraindicated in patients with a history of prolonged QT, 
recent myocardial infarction, or uncompensated heart failure, 
and in patients taking medications known to prolong the QT 
interval (Pﬁ  zer 2007).
Adverse effects–comparison with other 
antipsychotics
Recent reviews on the adverse effect proﬁ  les of atypical 
antipsychotics indicate that ziprasidone has advantages over 
several of the other medications in its class, especially in 
the area of metabolic side effects (McIntyre and Konarski 
2005; Marken and Pies 2006). The review by Marken and 
Pies compared the risk of adverse events with the atypical 
antipsychotics and haloperidol in 8 categories. Ziprasidone 
was classiﬁ  ed, along with haloperidol and aripiprazole, as 
having the lowest risk for development of diabetes and 
worsening of lipid proﬁ  les. Ziprasidone and aripiprazole 
had the lowest risk for weight gain. The risk was rated as 
minor or lower with ziprasidone in the following other cat-
egories: sedation/somnolence, EPS, anticholinergic effects, 
orthostasis and prolactin elevation. The review by McIntyre 
and Konarski similarly rated ziprasidone and aripiprazole 
as having the lowest risk of all the atypical antipsychotics 
in 6 of 8 categories studied: weight gain, dyslipidemia, 
glucose dysregulation, myocarditis/cardiomyopathy (along 
with olanzapine, risperidone and quetiapine), somnolence/
sedation and prolactin (along with clozapine and quetiap-
ine). Aripiprazole also had the lowest risk of developing 
QTc prolongation. Quetiapine and clozapine were rated 
as having the lowest risk of developing extrapyramidal 
symptoms.
Ziprasidone-induced mania
Manic symptom induction has been reported with atypical 
antipsychotics, including ziprasidone. A review of atypical 
antipsychotic induced mania or hypomania revealed 34 
reports and 53 cases from 1994–2005 (Michalopoulou 
and Lykouras 2006). Of these reports there were 22 cases 
associated with risperidone, 14 with olanzapine, 11 with 
ziprasidone, 5 with quetiapine, 1 with amisulpride and none 
with clozapine or aripiprazole. Although the authors were 
unable to report the rate of medication-induced mania, it is 
noteworthy that at the time of the review, ziprasidone had 
been on the market during only 5 of the years that were 
studied by the authors. Clozapine and risperidone had been 
available during all 12 years studied, while olanzapine (10 
years) and quetiapine (8 years) had been available for several 
years more than ziprasidone. The primary diagnoses of the 
patients in the 11 cases of ziprasidone-induced mania/hypo-
mania were as follows: 3 patients had Bipolar I disorder, one 
patient had Bipolar II disorder, four had unipolar depression, 
two had schizophrenia and one had schizoaffective disorder, 
bipolar type. The dosages prescribed to the patients were in 
the 20–160 mg per day range with a mean dose of 76 mg 
per day. The average onset from the start of treatment with 
ziprasidone to the induction of manic/hypomanic symptoms 
was 4.3 days (range 10 hours to 10 days), which was some-
what lower than the time-until-onset of symptoms with the 
other antipsychotics reported. Discontinuation of ziprasidone 
in 7 of the 11 cases resulted in successful management of 
mania/hypomania. In the four remaining cases, the symptoms 
resolved when the ziprasidone dose was lowered. Possible 
mechanisms of mania induction were discussed, including 
the 5HT-2A afﬁ  nity of atypical antipsychotics. As mentioned 
above, ziprasidone is known to have the highest afﬁ  nity for 
5HT-2A receptors among the antipsychotics. The inhibition 
of serotonin and norepinephrine reuptake by ziprasidone, has 
been hypothesized as contributing to the induction of mania 
(Baldassano et al 2003).
Special populations
Pregnancy
Ziprasidone is categorized by the FDA and American 
Academy of Pediatrics (AAP), along with the other atypical 
antipsychotics (except for clozapine, which is a category B) 
as Pregnancy Category C (human fetal teratogenicity can-
not be ruled out) (Pﬁ  zer 2005) A recent prospective study 
examined the effects of atypical antipsychotic medication 
taken by pregnant women (McKenna et al 2005). The study 
included 151 women treated with atypical antipsychotics in 
three countries. An increase in major malformations was not 
found, but an increased rate of low birth weight (10% versus 
2%, p   0.05) was observed in babies of mothers treated Neuropsychiatric Disease and Treatment 2007:3(6) 832
Nicolson and Nemeroff
with atypical antipsychotics. No mothers in this study were 
treated with ziprasidone. Little data have been gathered on 
the effects of ziprasidone treatment during pregnancy (Ernst 
and Goldberg 2002).
Patients with liver disease
Ziprasidone is metabolized by the CYP 3A4 isoenzyme, 
but no clinically significant alterations in metabolism 
occur in mild-to-moderate hepatic impairment (Everson 
et al 2000).
Ziprasidone in overdose
As many as 1 in 5 patients with bipolar disorder will die 
from suicide (Isometsa et al 1994). Nearly 50% of bipolar 
patients will attempt to take their own lives (Simpson and 
Jamison 1999). Because suicide attempts are common in 
patients with bipolar disorder, clinicians must be aware 
of the potential lethality of medications dispensed to their 
patients. Four cases of ziprasidone overdoses including two 
in combination with benzodiazepines were reported from 
the Pﬁ  zer-Spain database without cardiac events or abnor-
mal QTc recordings (Gomez-Criado et al 2005). Another 
case of a 57-year old woman who ingested an overdose 
of 4440 mg of ziprasidone recorded a maximum QTc of 
457.20 msec 12 hours after the ingestion, but QTc remained 
under 440 msec after 48 hours (Prieto et al 2005). Cases of 
ingestions as high as 12,800 mg have been reported without 
signiﬁ  cant EEG changes (Arbuck 2005).
Conclusion
In summary, ziprasidone appears to be a safe and effective 
option to treat bipolar disorder, especially acute mania. 
Ziprasidone does appear to have minimal effects on metabolic 
parameters, although the database of the long-term effects 
of ziprasidone on weight and serum lipids is limited. Initial 
concerns over the potential adverse cardiac effects of ziprasi-
done appear unwarranted. However additional investigation is 
needed to identify populations at risk for cardiac complications 
with ziprasidone. Clariﬁ  cation is also needed to determine the 
risk of EPS, especially akathisia in patients taking ziprasidone. 
Also needed are further studies in bipolar depression and main-
tenance therapy to prevent the recurrence of mood episodes. 
As a relatively new medication, the use of ziprasidone in 
special populations such as pregnant patients, children or the 
elderly has not been well studied. The potential of ziprasidone 
to cause treatment–emergent mania warrants investigation. 
Establishing the safety and efﬁ  cacy of once-daily dosing of 
ziprasidone would also be helpful for clinicians.
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